Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | CTH | P32929 | 1/20 | 0.36 |
| ▸ | CBS | P35520 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 2/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4952337 | 0.97 | TSHR (0.38) | HSD17B10BLMPMP22TSHRCTH | |
| SCHEMBL25148114 | 0.89 | MEN1 (0.35) | HSD17B10BLMPMP22TSHRALDH1A1 | |
| SCHEMBL871278 | 0.89 | MEN1 (0.35) | HSD17B10BLMPMP22TSHRALDH1A1 | |
| SCHEMBL4952136 | 0.87 | — | — | |
| SCHEMBL6664456 | 0.87 | HSD17B10 (0.46) | HSD17B10BLMPMP22TSHRCTH | |
| SCHEMBL20534906 | 0.87 | HSD17B10 (0.46) | HSD17B10BLMPMP22TSHRCTH | |
| SCHEMBL81956 | 0.87 | HSD17B10 (0.46) | HSD17B10BLMPMP22TSHRCTH | |
| SCHEMBL4952330 | 0.87 | CES2 (0.32) | HSD17B10TSHRALDH1A1TP53HIF1A | |
| SCHEMBL6666413 | 0.87 | HSD17B10 (0.46) | HSD17B10BLMPMP22TSHRCTH | |
| SCHEMBL14950228 | 0.87 | HSD17B10 (0.46) | HSD17B10BLMPMP22TSHRCTH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146768-A1 | PROCESSES FOR PREPARING POLYMERS USING ALPHA,OMEGA-DIFUNCTIONAL ALDARAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-06-19 | — | — | US | disclosed |
| EP-1858955-A1 | PROCESSES USING ALPHA, OMEGA-DIFUNCTIONAL ALDARAMIDES AS MONOMERS AND CROSSLINKERS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20060264672-A1 | Processes using alpha, omega-difunctional aldaramides as monomers and crosslinkers | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-11-23 | — | — | US | disclosed |
| WO-2006091901-A1 | PROCESSES USING ALPHA, OMEGA-DIFUNCTIONAL ALDARAMIDES AS MONOMERS AND CROSSLINKERS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-0079397-A1 | Asymmetrically substituted (2,4,6-triodoanilides) of dicarboxylic acids, their preparation and X-ray contrast agents containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1983-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264672-A1 | Processes using alpha, omega-difunctional aldaramides as monomers and crosslinkers | ALOX5, GSTO1, FASN | HSD17B10 1308/4885BLM 1570/4885PMP22 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.